Cue Biopharma, Inc.
CUE
Positions held
Your positionsCUE isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $200.32M | Enterprise value | $147.88M | Trailing P/E | — | Forward P/E | -57.45 |
| PEG | — | Price / book | 62.39 | Beta | 2.63 | Dividend yield | 0.00% |
| Revenue growth | 1.7% | Earnings growth | — | Gross margin | -99.2% | Operating margin | -11.1% |
| Profit margin | 0.0% | ROE | -16.0% | ROA | -1.7% | Debt / equity | 1.33 |
| Current ratio | 1.26 | Free cash flow | -$33.43M | Analyst recommendation | strong_buy | Mean target | $88.00 |
| 52w high | $45.50 | 52w low | $4.98 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $7.9M | $5.7M | $21.9M | $2.1M | $3.0M |
| Op margin | -1113.3% | -94.3% | 8.9% | -351.0% | -292.3% |
| Net income | -$153M | -$5.2M | $1.6M | -$7.4M | -$8.5M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$87.7M | -$5.4M | $2.0M | -$7.5M | -$8.6M |
- Revenue +39% vs prior quarter ($7.9M vs $5.7M).
- Operating margin compressed to -1113.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $27.5M | $9.3M | $5.5M | $1.2M | — |
| Op margin | -96.6% | -447.9% | -947.0% | -4297.3% | — |
| Net income | -$26.6M | -$40.7M | -$50.7M | -$53.0M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$26.5M | -$41.6M | -$52.0M | -$53.5M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-28 · Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU Response
2026-09-26 · Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?
2026-09-22 · An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
2026-09-21 · Top Midday Decliners
2026-09-21 · Top Premarket Gainers
2026-09-21 · Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results
2026-09-21 · Cue Biopharma Meets Primary Goal in a Phase 2 Study of Chronic Hives Disease Drug Candidate
2026-09-20 · Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
2026-08-03 · Cue Biopharma Names James Ahlers CFO Following FDA Filing for CUE-221 in Food Allergy
2026-07-24 · 3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership
Price (daily)
Full chart · RSI · MACD · patterns